Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental ...

The KRAS gene mutation, responsible for a quarter of all cancerous tumors, has met its match. Thanks to UCSF research, a tiny ...

Shares of Nuvalent rose after the pharmaceutical company announced positive topline results for a clinical trial of neladalkib for lung-cancer patients. The stock was up 14%, to $109.84, late Monday ...

Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

Beyond a cancer cell’s genetic blueprint, the expression levels of certain proteins on its surface is emerging as a collection of critical, actionable biomarkers. Instead of looking for a mutated gene ...

Race Oncology reaches two major new clinical programs for RC220 in lung cancer and AML boding well for its clinical ... Read ...

A closely watched Summit Therapeutics lung cancer drug showed trending improvement on a pivotal study’s measure of how long patients treated with the therapy lived, but the result in the final ...

Treatment innovations in advanced lung cancer and melanoma over the past 2 decades have significantly improved OS, but they ...

The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, locally advanced, or metastatic non-squamous non-small cell lung cancer ...

One person’s side effect could be another person’s treatment if we expand our perspective on small molecule drug targets, ...

Patients with type 2 diabetes who use GLP-1 receptor agonists have a significantly lower risk for lung cancer than those who ...